rs2359612
| Orientation | plus |
| Stabilized | plus |
| Geno | Mag | Summary |
|---|---|---|
| (A;A) | 0 | common in clinvar |
| Make rs2359612(A;G) |
| Make rs2359612(G;G) |
| Reference | GRCh38 38.1/141 |
| Chromosome | 16 |
| Position | 31092475 |
| Gene | VKORC1 |
| is a | snp |
| is | mentioned by |
| dbSNP | rs2359612 |
| dbSNP (classic) | rs2359612 |
| ClinGen | rs2359612 |
| ebi | rs2359612 |
| HLI | rs2359612 |
| Exac | rs2359612 |
| Gnomad | rs2359612 |
| Varsome | rs2359612 |
| LitVar | rs2359612 |
| Map | rs2359612 |
| PheGenI | rs2359612 |
| Biobank | rs2359612 |
| 1000 genomes | rs2359612 |
| hgdp | rs2359612 |
| ensembl | rs2359612 |
| geneview | rs2359612 |
| scholar | rs2359612 |
| rs2359612 | |
| pharmgkb | rs2359612 |
| gwascentral | rs2359612 |
| openSNP | rs2359612 |
| 23andMe | rs2359612 |
| SNPshot | rs2359612 |
| SNPdbe | rs2359612 |
| MSV3d | rs2359612 |
| GWAS Ctlg | rs2359612 |
| GMAF | 0.4986 |
| Max Magnitude | 0 |
| ? | (A;A) (A;G) (G;G) | 28 |
|---|---|---|
|
| ||
[PMID 22321278] [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy]
[PMID 17048007
] Association of warfarin dose with genes involved in its action and metabolism.
[PMID 17549303] Functional promoter polymorphism in the VKORC1 gene is no major genetic determinant for coronary heart disease in Northern Germans.
[PMID 18252229] Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.
[PMID 18466099] Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.
[PMID 18523153] Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.
[PMID 18559094] Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction.
[PMID 18574025] The largest prospective warfarin-treated cohort supports genetic forecasting.
[PMID 18752379] Warfarin pharmacogenetics.
[PMID 18841283] Single nucleotide polymorphisms in the VKORC1 gene and the risk of stroke in the Southern German population.
[PMID 18855533] VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.
[PMID 19074728] Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy.
[PMID 19228618] Estimation of the warfarin dose with clinical and pharmacogenetic data.
[PMID 19300499] A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.
[PMID 19738376] Pharmacogenetic testing for guiding de novo phenprocoumon therapy in stroke patients.
[PMID 19955245] Warfarin sensitivity genotyping: a review of the literature and summary of patient experience.
[PMID 22178823] [Distribution of variant alleles association with warfarin pharmacokinetics and pharmacodynamics in the Han population in China].
[PMID 26040031] [Association of allelic polymorphisms of genes matrix Gla-protein system with ischemic atherothrombotic stroke]
| ClinVar | |
|---|---|
| Risk | rs2359612(G;G) |
| Alt | rs2359612(G;G) |
| Reference | Rs2359612(A;A) |
| Significance | Drug-response |
| Disease | warfarin response - Dosage |
| Variation | info |
| Gene | VKORC1 |
| CLNDBN | warfarin response - Dosage |
| Reversed | 0 |
| HGVS | NC_000016.9:g.31103796A>G |
| CLNSRC | PharmGKB Clinical Annotation |
| CLNACC | RCV000211406.1, |
[PMID 27889279] Vitamin K epoxide reductase expression and prostate cancer risk.
